In addition, all patients were classified according to AML qualifiers (de novo AML vs. AML progressing from MDS or MDS/MPN and therapy-related AML according to the ICC 2022 classification [21]) and iASPP expression levels were assessed. The gene discussed is PPP1R13L; the disease is myelodysplastic syndrome.